AI ASSISTANT

Ask DrugCentral

Explore drug properties, targets, and indications with answers grounded in DrugCentral.

Your question

Ask in your own words. Each question is answered independently.

Explore sample questions

Select a question to fill the editor, then ask it or make it your own.

DrugCentral answer

Your answer will appear here. Open linked drug cards in a new tab to explore the source details.

AI can make mistakes. Verify answers against the original sources before relying on them.

Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	2712	87679-37-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trandolapril gopten mavik odrik	The effect of trandolapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity thereby reducing angiotensin II formation, decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin. Decreased aldosterone secretion leads to diuresis, natriuresis, and a small increase of serum potassium. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity. Molecular weight: 430.55 Formula: C24H34N2O5 CLOGP: 2.10 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 95.94 ALOGS: -4.32 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trandolapril
gopten
mavik
odrik

The effect of trandolapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity thereby reducing angiotensin II formation, decreasing vasoconstriction, decreasing aldosterone secretion, and increasing plasma renin. Decreased aldosterone secretion leads to diuresis, natriuresis, and a small increase of serum potassium. Trandolapril is deesterified to the diacid metabolite, trandolaprilat, which is approximately eight times more active as an inhibitor of ACE activity.

Molecular weight: 430.55
Formula: C24H34N2O5
CLOGP: 2.10
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 95.94
ALOGS: -4.32
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.06 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	10 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.25 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.17 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.26 hours	Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.495		High	0.96
caco2-efflux	Caco-2 efflux ratio (BA/AB)	3.811		High	0.96
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	10.691	10^-6 cm/s	High	0.96
dh-clint	Dog hepatocyte intrinsic clearance	16.749	uL/min/10^6 cells	High	0.96
dppb	Dog plasma protein binding (% unbound)	7.420	%	High	0.96
fcs-ppb	Fetal calf serum protein binding (% unbound)	8.030	%	High	0.96
herg	hERG pIC50	4.313	pIC50	High	0.96
hh-clint	Human hepatocyte intrinsic clearance	20.045	uL/min/10^6 cells	High	0.96
hlm-clint	Human liver microsomal intrinsic clearance	24.491	uL/min/mg protein	High	0.96
hppb	Human plasma protein binding (% unbound)	8.610	%	High	0.96
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK,TGFBR1	24
kinase-selectivity-class	AXL,BRAF,GRK2,MAP2K6	4
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	5.309		Moderate	0.68
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	2.089		High	0.96
mh-clint	Mouse hepatocyte intrinsic clearance	72.277		High	0.96
mppb	Mouse plasma protein binding (% unbound)	6.600		High	0.96
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	11.776		High	0.96
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	9.960	%	High	0.96
rat-kpuu-brain	Rat brain Kpuu	0.009	%	Moderate	0.68
rh-clint	Rat hepatocyte intrinsic clearance	101.859	uL/min/10^6 cells	High	0.96
rh-fuinc	Rat hepatocyte fraction unbound in incubation	78.750	%	High	0.96
rppb	Rat plasma protein binding (% unbound)	7.660	%	High	0.96
solubility-dd	Solubility at pH 7.4 in DMSO	1009.253	uM	High	0.96

Approvals:

Date	Agency	Company	Orphan
April 26, 1996	FDA	ABBVIE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paranoia	70.59	20.46	25	3909	12883	90611630
Lactic acidosis	69.94	20.46	37	3897	50426	90574087
Hallucination, auditory	58.29	20.46	23	3911	15952	90608561
Psychotic disorder	55.21	20.46	27	3907	31203	90593310
Focal segmental glomerulosclerosis	48.17	20.46	12	3922	1839	90622674
Cerebellar haematoma	41.09	20.46	8	3926	392	90624121
Endometrial ablation	38.81	20.46	9	3925	1020	90623493
Red blood cells urine positive	37.16	20.46	11	3923	3214	90621299
Hyperaesthesia	34.17	20.46	14	3920	10688	90613825
Bacterial test	32.79	20.46	8	3926	1125	90623388
White blood cells urine positive	29.60	20.46	11	3923	6487	90618026
Acute kidney injury	29.35	20.46	51	3883	320336	90304177
Dyspnoea	29.19	20.46	94	3840	880861	89743652
Ventricular hypokinesia	27.89	20.46	10	3924	5331	90619182
Urine abnormality	27.73	20.46	11	3923	7726	90616787
Cardiac failure chronic	27.35	20.46	10	3924	5636	90618877
Orthopnoea	25.49	20.46	10	3924	6825	90617688
Cough	25.42	20.46	52	3882	368910	90255603
Pneumonia	24.73	20.46	72	3862	637987	89986526
Asthma	24.08	20.46	40	3894	242120	90382393
Oxygen saturation decreased	23.39	20.46	26	3908	107457	90517056
Exposure to SARS-CoV-2	22.42	20.46	7	3927	2445	90622068
Dorsal ramus syndrome	21.77	20.46	4	3930	143	90624370
Congestive cardiomyopathy	21.38	20.46	9	3925	7345	90617168
Organising pneumonia	21.10	20.46	9	3925	7588	90616925
Cardiogenic shock	20.64	20.46	13	3921	24455	90600058
Pharyngeal paraesthesia	20.64	20.46	7	3927	3167	90621346

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oesophageal obstruction	73.44	18.69	16	4240	586	42616493
Bezoar	61.48	18.69	16	4240	1260	42615819
Hypertensive encephalopathy	54.29	18.69	12	4244	470	42616609
Substance use	51.98	18.69	15	4241	1736	42615343
Arterial disorder	38.05	18.69	11	4245	1281	42615798
Oesophageal haemorrhage	28.54	18.69	9	4247	1405	42615674
Cough	27.36	18.69	57	4199	178046	42439033
Reading disorder	27.01	18.69	7	4249	542	42616537
Lid sulcus deepened	25.66	18.69	5	4251	104	42616975
Jugular vein distension	25.48	18.69	7	4249	677	42616402
Colectomy total	24.78	18.69	6	4250	352	42616727
Wrong product administered	24.16	18.69	12	4244	6214	42610865
Lactic acidosis	24.07	18.69	26	4230	45235	42571844
Eosinophil count increased	23.03	18.69	14	4242	10749	42606330
Waist circumference increased	22.97	18.69	7	4249	977	42616102
Body mass index increased	21.48	18.69	7	4249	1214	42615865
Hypotension	21.16	18.69	65	4191	257566	42359513
Bronchial wall thickening	20.74	18.69	7	4249	1353	42615726
Suspected COVID-19	20.39	18.69	7	4249	1423	42615656
Libido decreased	20.30	18.69	10	4246	5088	42611991
Dysgraphia	19.91	18.69	8	4248	2520	42614559
Drug interaction	18.87	18.69	64	4192	266935	42350144

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Lactic acidosis	89.06	17.08	63	7381	92748	110489107
Oesophageal obstruction	68.16	17.08	16	7428	1227	110580628
Psychotic disorder	66.76	17.08	42	7402	50895	110530960
Cough	51.86	17.08	103	7341	461538	110120317
Bezoar	49.43	17.08	16	7428	4038	110577817
Substance use	48.05	17.08	14	7430	2492	110579363
Paranoia	46.78	17.08	25	7419	22349	110559506
Acute kidney injury	39.89	17.08	113	7331	635317	109946538
Reading disorder	38.23	17.08	10	7434	1195	110580660
Hallucination, auditory	37.70	17.08	23	7421	26374	110555481
Arterial disorder	36.45	17.08	11	7433	2208	110579647
Endometrial ablation	35.61	17.08	9	7435	939	110580916
Hyperkalaemia	34.37	17.08	44	7400	135752	110446103
Cerebellar haematoma	33.92	17.08	8	7436	626	110581229
Oesophageal haemorrhage	29.40	17.08	9	7435	1894	110579961
Bacterial test	28.92	17.08	8	7436	1181	110580674
Hypotension	28.86	17.08	89	7355	523760	110058095
Red blood cells urine positive	27.31	17.08	11	7433	5174	110576681
Hypoglycaemia	25.34	17.08	35	7409	116069	110465786
Colectomy total	25.09	17.08	6	7438	498	110581357
Dysgraphia	24.85	17.08	10	7434	4695	110577160
Lid sulcus deepened	24.31	17.08	5	7439	207	110581648
White blood cells urine positive	23.37	17.08	11	7433	7513	110574342
Libido decreased	22.61	17.08	10	7434	5925	110575930
Jugular vein distension	22.26	17.08	7	7437	1609	110580246
Waist circumference increased	21.52	17.08	7	7437	1794	110580061
Hyperaesthesia	21.46	17.08	13	7431	14714	110567141
Urine abnormality	21.39	17.08	11	7433	9085	110572770
Drug interaction	20.49	17.08	77	7367	500106	110081749
Cardiogenic shock	20.17	17.08	22	7422	57316	110524539
Oxygen saturation decreased	19.98	17.08	37	7407	156945	110424910
Hypertensive encephalopathy	19.88	17.08	6	7438	1205	110580650
Body mass index increased	19.75	17.08	7	7437	2323	110579532
Eosinophil count increased	19.49	17.08	14	7430	21044	110560811
Focal segmental glomerulosclerosis	19.13	17.08	8	7436	4137	110577718
Dizziness	19.01	17.08	95	7349	698098	109883757
Spinal pain	18.74	17.08	13	7431	18502	110563353
Coagulopathy	18.56	17.08	18	7426	40893	110540962
Blood pressure decreased	18.40	17.08	30	7414	115061	110466794
Exposure to SARS-CoV-2	18.21	17.08	7	7437	2912	110578943
Dyspnoea	17.65	17.08	131	7313	1106741	109475114
Bronchial wall thickening	17.57	17.08	7	7437	3200	110578655
Itching scar	17.15	17.08	3	7441	51	110581804
Cardiac failure chronic	17.12	17.08	11	7433	13800	110568055

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA10	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BB10	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers
FDA MoA	N0000000181	Angiotensin-converting Enzyme Inhibitors
FDA EPC	N0000175562	Angiotensin Converting Enzyme Inhibitor
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
CHEBI has role	CHEBI:35457	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:50266	prodrug
CHEBI has role	CHEBI:49103	drug metabolite
CHEBI has role	CHEBI:76967	human xenobiotic metabolite

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs

benazepril captopril cilazapril delapril enalapril fosinopril imidapril lisinopril moexipril perindopril quinapril ramipril show all 15 →

C09BB ACE inhibitors and calcium channel blockers 13 drugs

amlodipine benazepril delapril enalapril felodipine lercanidipine lisinopril manidipine nitrendipine perindopril ramipril verapamil show all 13 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Left ventricular cardiac dysfunction	indication	429589006
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diabetic renal disease	off-label use	127013003
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Hyperkalemia	contraindication	14140009
Ventricular tachycardia	contraindication	25569003
Complete atrioventricular block	contraindication	27885002
Acute cerebrovascular insufficiency	contraindication	29322000
Sick sinus syndrome	contraindication	36083008	DOID:13884
Immunosuppression	contraindication	38013005
Angioedema	contraindication	41291007	DOID:1558
Low cardiac output syndrome	contraindication	44088000
Low blood pressure	contraindication	45007003
Bradycardia	contraindication	48867003
Lown-Ganong-Levine syndrome	contraindication	55475008	DOID:13087
Aortic valve stenosis	contraindication	60573004	DOID:1712
Wolff-Parkinson-White pattern	contraindication	74390002	DOID:384
Duchenne muscular dystrophy	contraindication	76670001	DOID:11723
Transplantation	contraindication	77465005
Chronic idiopathic constipation	contraindication	82934008
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Left heart failure	contraindication	85232009
Cardiogenic shock	contraindication	89138009
Hyponatremia	contraindication	89627008
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Disorder of connective tissue	contraindication	105969002	DOID:65
Liver function tests abnormal	contraindication	166603001
Second degree atrioventricular block	contraindication	195042002
Hypertrophic cardiomyopathy	contraindication	233873004	DOID:11984
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Neuromuscular Transmission Deficiency	contraindication
Hemodialysis with High-Flux Membrane	contraindication
First Degree Atrioventricular Heart Block	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.23	acidic
pKa2	5.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	8.12		WOMBAT-PK	CHEMBL

External reference:

ID	Source
4020971	VUID
N0000148444	NUI
D00383	KEGG_DRUG
4020971	VANDF
C0076891	UMLSCUI
CHEBI:9649	CHEBI
X93	PDB_CHEM_ID
CHEMBL1519	ChEMBL_ID
DB00519	DRUGBANK_ID
C052035	MESH_SUPPLEMENTAL_RECORD_UI
5484727	PUBCHEM_CID
6453	IUPHAR_LIGAND_ID
5746	INN_ID
1T0N3G9CRC	UNII
DB14209	DRUGBANK_ID
1546379	RXNORM
107488	MMSL
5448	MMSL
5606	MMSL
5642	MMSL
d04008	MMSL
004452	NDDF
108562001	SNOMEDCT_US
386871006	SNOMEDCT_US
C0165477	UMLSCUI
CHEMBL1201387	ChEMBL_ID
87679-71-8	SECONDARY_CAS_RN
5464097	PUBCHEM_CID
6455	IUPHAR_LIGAND_ID
6370	INN_ID
C061095	MESH_SUPPLEMENTAL_RECORD_UI
RR6866VL0O	UNII
CHEBI:141521	CHEBI
1T0N3G9CRC	INXIGHT DRUGS
RR6866VL0O	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	42806-052	TABLET	1 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	42806-053	TABLET	2 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	42806-054	TABLET	4 mg	ORAL	ANDA	18 sections
Trandolapril	Human Prescription Drug Label	1	50090-4120	TABLET	2 mg	ORAL	ANDA	21 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4128	TABLET	1 mg	ORAL	ANDA	19 sections
Mavik	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5099	TABLET	4 mg	ORAL	NDA	20 sections
Tarka	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5311	TABLET, FILM COATED, EXTENDED RELEASE	2 mg	ORAL	NDA	20 sections
Tarka	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5320	TABLET, FILM COATED, EXTENDED RELEASE	4 mg	ORAL	NDA	20 sections
Tarka	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5548	TABLET, FILM COATED, EXTENDED RELEASE	2 mg	ORAL	NDA	20 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6061	TABLET	4 mg	ORAL	ANDA	14 sections
Trandolapril	Human Prescription Drug Label	1	57237-089	TABLET	1 mg	ORAL	ANDA	20 sections
Trandolapril	Human Prescription Drug Label	1	57237-090	TABLET	2 mg	ORAL	ANDA	20 sections
Trandolapril	Human Prescription Drug Label	1	57237-091	TABLET	4 mg	ORAL	ANDA	20 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8003	TABLET	2 mg	ORAL	ANDA	18 sections
Trandolapril	Human Prescription Drug Label	1	65862-164	TABLET	1 mg	ORAL	ANDA	20 sections
Trandolapril	Human Prescription Drug Label	1	65862-165	TABLET	2 mg	ORAL	ANDA	20 sections
Trandolapril	Human Prescription Drug Label	1	65862-166	TABLET	4 mg	ORAL	ANDA	20 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68151-0757	TABLET	1 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-566	TABLET	1 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-566	TABLET	1 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-567	TABLET	2 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-567	TABLET	2 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-568	TABLET	4 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68180-568	TABLET	4 mg	ORAL	ANDA	18 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	68258-6100	TABLET	4 mg	ORAL	ANDA	20 sections
Trandolapril and Verapamil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	68462-294	TABLET, FILM COATED, EXTENDED RELEASE	1 mg	ORAL	ANDA	20 sections
Trandolapril and Verapamil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	68462-295	TABLET, FILM COATED, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
Trandolapril and Verapamil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	68462-296	TABLET, FILM COATED, EXTENDED RELEASE	2 mg	ORAL	ANDA	20 sections
Trandolapril and Verapamil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	68462-329	TABLET, FILM COATED, EXTENDED RELEASE	4 mg	ORAL	ANDA	20 sections
Trandolapril	HUMAN PRESCRIPTION DRUG LABEL	1	71335-1431	TABLET	2 mg	ORAL	ANDA	20 sections

Ask DrugCentral

Your question

DrugCentral answer

About Ask DrugCentral

General architecture

Using the assistant

trandolapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: